Cancer Therapy Products Make Huge Investment in Medical Journal Advertising Through Q1 2014

by Client Services

In Q1 2014, there were a total of 22,360 ad pages purchased in professional health journals, a 1% decrease year-over-year, according to Kantar Media. Cancer therapy products took the lead spot in both pages and dollars. Oral Diabetes products continue to make larger investment in print advertising. Through the first three months of the year, this product class has purchased 886 pages. 

Top 5 Print Ad Drug Classes (Pages): March 2014

#1 Cancer Therapy Products – 1,972 pages (-15%)

#2 Diabetes Oral – 886 pages (+491%)

#3 Anticoagulants Oral – 595 pages (-40%)

#4 Biological Response Modifiers – 445 pages (+15%)

#5 SSRI/SNRI – 443 pages (+366%)

The percentage changes compare March 2014 to that same time period in 2013. For more information on these ad insights or other data, let one of us know.

Kantar Media sets the standard for accurate, comprehensive competitive advertising intelligence in the professional healthcare arena. Check back next month for updated data on the top products, classes, companies and category movers year-to-date.